These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16728538)

  • 1. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.
    Feenstra J; van Aken MO; de Herder WW; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2006 Jun; 154(6):805-6. PubMed ID: 16728538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
    Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
    Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
    Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
    Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2009 Jun; 19(3):245-51. PubMed ID: 19109045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
    Frohman LA; Bonert V
    Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
    Trainer PJ; Ezzat S; D'Souza GA; Layton G; Strasburger CJ
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):549-57. PubMed ID: 19438906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
    Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipodystrophy in patients with acromegaly receiving pegvisomant.
    Bonert VS; Kennedy L; Petersenn S; Barkan A; Carmichael J; Melmed S
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3515-8. PubMed ID: 18611977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
    Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
    Madsen M; Poulsen PL; Orskov H; Møller N; Jørgensen JO
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2405-13. PubMed ID: 21632808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The German ACROSTUDY: past and present.
    Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.
    Madsen M; Krusenstjerna-Hafstrøm T; Møller L; Christensen B; Vendelbo MH; Pedersen SB; Frystyk J; Jessen N; Hansen TK; Stødkilde-Jørgensen H; Flyvbjerg A; Jørgensen JO
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1227-35. PubMed ID: 22298804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin reaction and fever after treatment with pegvisomant in a patient with acromegaly.
    Manavela MP; Danilowicz K; Bruno OD
    Clin Ther; 2010 Feb; 32(2):246-9. PubMed ID: 20206782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
    van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
    J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegvisomant and improvement of quality of life in acromegalic patients.
    Neggers SJ; van der Lely AJ
    Horm Res Paediatr; 2011; 76 Suppl 1():102-5. PubMed ID: 21778759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of medical therapy in the management of acromegaly.
    Vance ML; Laws ER
    Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegvisomant: new preparation. A last resort in acromegaly.
    Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.